Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 4,085 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 2 Interventional Results available

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 15, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

NCT06408168
View directory record Official record
Conditions
Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Interventions
Fulvestrant, Repotrectinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

NCT05716516
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Estradiol
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Early Phase 1 Interventional

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

NCT06137040
View directory record Official record
Conditions
Asthma in Children, Asthma Attack
Interventions
Magnesium Sulfate within the first hour, No Magnesium sulfate within the first hour
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 15, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Results available

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

NCT02289989
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oregano extract cream, Hydrocortisone
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

NCT00080925
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

NCT00511706
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 15, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone

NCT03704584
View directory record Official record
Conditions
Tenosynovitis
Interventions
Treatment Group: Corticosteroid injection, Control Group (corticosteroid alone), Treatment Group: Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Collaborative Connected Health (CCH) for PCORI

NCT02358135
View directory record Official record
Conditions
Psoriasis
Interventions
Collaborative Connected health, (CCH), Control
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 10:58 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 15, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

NCT03201250
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions
Cabozantinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

NCT04760691
View directory record Official record
Conditions
HIV, Prophylaxis, Transgender
Interventions
Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

NCT01507558
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Administration of dexamethasone to SFA/popliteal adventitia
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT01363128
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Phase 3 Interventional

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

NCT02670707
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Cytarabine, Vinblastine/prednisone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 15, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

NCT02412228
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
John L. Reagan
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 10:58 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Early Phase 1 Interventional

Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer

NCT03028519
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Vitamin D3
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 15, 2026, 10:58 AM EDT